CA2699761A1 - Formulation contenant un compose inhibiteur de la kinase dependante de la cycline et procede de traitement de tumeurs l'utilisant - Google Patents

Formulation contenant un compose inhibiteur de la kinase dependante de la cycline et procede de traitement de tumeurs l'utilisant Download PDF

Info

Publication number
CA2699761A1
CA2699761A1 CA2699761A CA2699761A CA2699761A1 CA 2699761 A1 CA2699761 A1 CA 2699761A1 CA 2699761 A CA2699761 A CA 2699761A CA 2699761 A CA2699761 A CA 2699761A CA 2699761 A1 CA2699761 A1 CA 2699761A1
Authority
CA
Canada
Prior art keywords
formula
compound
formulation
hours
organic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699761A
Other languages
English (en)
Inventor
Valentyn Antochshuk
Rajat Bannerji
Anita Dabbara
Paul Kirschmeier
David A. Parry
Mohammed Shameem
Paul Statkevich
Siu-Long Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2699761A1 publication Critical patent/CA2699761A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2699761A 2007-09-17 2008-09-16 Formulation contenant un compose inhibiteur de la kinase dependante de la cycline et procede de traitement de tumeurs l'utilisant Abandoned CA2699761A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99418507P 2007-09-17 2007-09-17
US60/994,185 2007-09-17
US99946907P 2007-10-17 2007-10-17
US60/999,469 2007-10-17
US5378408P 2008-05-16 2008-05-16
US61/053,784 2008-05-16
PCT/US2008/010778 WO2009038701A2 (fr) 2007-09-17 2008-09-16 Formulation contenant un composé inhibiteur de la kinase dépendante de la cycline et procédé de traitement de tumeurs l'utilisant

Publications (1)

Publication Number Publication Date
CA2699761A1 true CA2699761A1 (fr) 2009-03-26

Family

ID=40020243

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699761A Abandoned CA2699761A1 (fr) 2007-09-17 2008-09-16 Formulation contenant un compose inhibiteur de la kinase dependante de la cycline et procede de traitement de tumeurs l'utilisant

Country Status (12)

Country Link
EP (1) EP2200584A2 (fr)
JP (1) JP2010539173A (fr)
KR (1) KR20100072253A (fr)
CN (1) CN101854915A (fr)
AU (1) AU2008301925A1 (fr)
BR (1) BRPI0816823A8 (fr)
CA (1) CA2699761A1 (fr)
CO (1) CO6270205A2 (fr)
MX (1) MX2010002927A (fr)
NZ (1) NZ584037A (fr)
SG (1) SG184760A1 (fr)
WO (1) WO2009038701A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
JO3190B1 (ar) * 2011-10-19 2018-03-08 Otsuka Pharma Co Ltd محلول للتناول عن طريق الفم
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
BRPI0816823A2 (pt) 2015-03-10
BRPI0816823A8 (pt) 2016-02-10
WO2009038701A3 (fr) 2009-09-11
MX2010002927A (es) 2010-06-01
KR20100072253A (ko) 2010-06-30
JP2010539173A (ja) 2010-12-16
EP2200584A2 (fr) 2010-06-30
CO6270205A2 (es) 2011-04-20
WO2009038701A2 (fr) 2009-03-26
CN101854915A (zh) 2010-10-06
AU2008301925A1 (en) 2009-03-26
NZ584037A (en) 2012-08-31
SG184760A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
EP1250140B1 (fr) Combinaison d'un inhibiteur de abl-, pdgf-recepteur- et/ou kit recepteur-tyrosine kinase et d'un compose organique capable de se lier a une glycoproteine alpha1-acide
CN101360422B (zh) 致癌Ras特异性细胞毒化合物及其使用方法
EP2640386B1 (fr) Combinaison d'inhibiteurs de la checkpoint kinase 1 et d'inhibiteurs de la wee 1 kinase
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
CN101146533A (zh) 吡唑激酶抑制剂和其它抗肿瘤剂的组合
AU2927999A (en) Use of epothilones for the treatment of cancer
KR20070119745A (ko) 수니티닙 말레이트를 사용하는 항암 병행 요법
TW200936139A (en) Method for cancer therapy
CA3058457A1 (fr) Combinaisons d'inhibiteurs de chk1 et wee1
CA2519930A1 (fr) Agents therapeutiques contenant un agent anti-angiogenique associe a un inhibiteur de src, et leur utilisation therapeutique
CA2566081A1 (fr) Utilisation de dipyridamole pour le traitement de la resistance a des inhibiteurs plaquettaires
JP2021512105A (ja) 消化管間質腫瘍の治療のための併用療法
Listro et al. Urea-based anticancer agents. Exploring 100-years of research with an eye to the future
US20100286038A1 (en) Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20050267140A1 (en) Method for treating abnormal cell growth
CN102227220A (zh) 用于治疗性治疗的Hsp90抑制剂
TW200426142A (en) Treatment of incontinence
CA2699761A1 (fr) Formulation contenant un compose inhibiteur de la kinase dependante de la cycline et procede de traitement de tumeurs l'utilisant
AU2007259224A1 (en) Use of a P38 kinase inhibitor for treating psychiatric disorders
JP2006504721A (ja) 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用
CN101460197A (zh) 有机化合物的组合
EP3880207A1 (fr) Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
US20090259054A1 (en) Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration
CA3082287C (fr) Polytherapies faisant appel a un inhibiteur de ezh2
KR20240041259A (ko) 종양 혈관 파괴용 약학 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140916